Advances in cancer genomics are delivering critical insights into all stages of tumor progression. Illumina technology and informatics help you see the bigger picture quickly, efficiently, and cost-effectively. With Illumina's NGS (next-generation sequencing) and array solutions, you can go both deep and wide into cancer genomics with whole-genome studies, targeted gene profiling, gene expression, and epigenetic analysis.
Cancer begins when certain genes within normal cells mutate, resulting in unregulated cell growth. As cancer progresses, cells accumulate additional somatic mutations and propagate to form new cancer clones. As a result, most advanced cancers are polyclonal. Since each of these clones will have a unique response to therapy and risk of metastasis, a complete understanding of all tumor clones is important.
Germline mutations that predispose individuals to cancer can be detected through various approaches, ranging from genome-wide association studies (GWAS) to whole-genome and targeted gene sequencing. Learn more about detecting germline mutations »
Tumor/normal sequencing studies are critical to distinguish between unique somatic mutations accrued by a tumor and germline mutations also present in the surrounding normal tissue. Illumina sequencers offer the speed and accuracy to detect these mutations. Learn more about detecting somatic mutations »
Analyzing the entire cancer transcriptome or targeted transcripts with RNA-Seq allows researchers to detect significant expression changes, and to potentially identify genes associated with tumor progression. Learn more about using RNA-Seq to detect gene expression & transcriptome changes »
Cancer cells frequently exhibit epigenetic changes such as aberrant methylation and altered transcription factor binding. Learn more about using next-generation sequencing (NGS) and array methods to detect epigenetic changes »
Genomic instability and chromosomal rearrangements are frequent features of cancer. Illumina offers both array- and sequencing-based approaches to identify gross chromosomal changes. Learn more about identifying chromosomal abnormalities »
NGS methods enable researchers to perform whole-genome studies, targeted gene profiling, gene expression, and epigenetic studies on polyclonal tumor samples at a pace unheard of a few years ago. Learn more about cancer sequencing methods »
The analysis of next-generation sequencing data from cancer samples can be challenging. Illumina offers a number of software options and analysis tools to simplify this process. Learn more about cancer data analysis »
Dr. Daber uses TruSeq Custom Amplicon to identify genomic changes in tumor specimens.
Access PDF »
A first-of-its kind program transforming our ability to understand, classify, and treat 12 types of cancer.
Explore TCGA »
NGS-based cancer studies offer a deeper understanding of tumor biology.
Access PDF »
A new UK program seeking to improve health outcomes of cancer patients and their families will use Illumina's TruSight Cancer.
View Article »
The MiSeq sequencer enables comprehensive profiling of tumor samples. Interrogate a wider range of mutations than is possible with traditional technologies.
View System »
For Research Use Only.
Quote attributed to Seishi Ogawa, Ph.D.:
“Cancer is caused by genetic mutations. To fully understand their functional consequences it is essential to view the complete spectrum of genetic alterations both at the DNA and RNA level, as well as copy number and methylation changes. Our research aims to understand the genetic basis of various human cancers using revolutionized sequencing technologies.”